Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib Window of Opportunity in SCCHN
NCT03179956Phase 1Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in head and neck squamous cell carcinoma (HNSCC), sponsored by Fox Chase Cancer Center. Primary endpoint: pRB1 levels. Started Apr 2018; status: terminated.
02
Drugs
ribociclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03179956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179956.